Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vascular Dynamics, Inc.
This is a prospective, randomized, double-blind, sham-controlled, multi-center post market study investigating the efficacy and safety of MobiusHD System, and the efficacy of the MobiusHD device in lowering mean systolic 24-hour ABP in subjects with resistant hypertension.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged 18-70 years;
Diagnosed with resistant hypertension;
A mean systolic 24-hour ABP of 135-170 mmHg following at least 30 days on a stable antihypertensive medication regimen (no changes in medications or dose).
A mean systolic 24-hour ABP of 135-170 mmHg after washout of all antihypertensive medications.
You may not be if
Known or clinically suspected baroreflex failure or autonomic neuropathy
Treatable cause of resistant hypertension
Hypertension secondary to an identifiable and treatable cause other than sleep apnea
Clareo Health | Controlling And Lowering Blood Pressure With the MobiusHDTM Device
